Merrimack: Clinical Trial Update (Merrimack) - Jul 18, 2015 - “Adverse events reported for MM-111 in combination with anti-cancer therapies are similar to adverse events reported for the standard of care combinations”; “No MTD was identified for the combination of MM-111 and standard doses of lapatinib +/- trastuzumab (Arm 2), paclitaxel + trastuzumab (Arm 3), lapatinib + paclitaxel + trastuzumab (Arm 4), or docetaxel + trastuzumab (Arm 5)”; “A MTD of capecitabine (800 mg/m2) was identified in combination with the recommended dose of MM-111 (10 mg/kg) and the standard dose of cisplatin and trastuzumab (Arm 1)”; “Preliminary PK analysis showed that MM-111 PK parameters (half-life, dose-adjusted Cmax, and dose adjusted AUC) were not affected by the SOC therapies used in combination with MM-111”; “The Recommended MM-111 Phase 2 doses are 20mg/kg QW and 40mg/Q3W"
P1 data • Oncology
|